Luke Miels, GSK chief commercial officer
GSK picks up Scynexis' FDA-approved antifungal drug for $90M upfront
GSK is dishing out $90 million cash to add an antifungal drug to its commercial portfolio, in a deal spotlighting the pharma giant’s growing focus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
